Literature DB >> 10508721

Mechanism of fluoroquinolone action.

K Drlica1.   

Abstract

When fluoroquinolones bind to gyrase or topoisomerase IV in the presence of DNA, they alter protein conformation. DNA cleavage results with diminished religation, so the enzymes are trapped in ternary complexes with drug and cleaved DNA. Preferential localization of gyrase ahead of replication forks and topoisomerase IV behind them causes fluoroquinolone-mediated complexes with the two enzymes to have different physiological consequences.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10508721     DOI： 10.1016/s1369-5274(99)00008-9

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN： 1369-5274            Impact factor:   7.934


  70 in total

1.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  SOS induction by stabilized topoisomerase IA cleavage complex occurs via the RecBCD pathway.

Authors:  Jeanette H Sutherland; Bokun Cheng; I-Fen Liu; Yuk-Ching Tse-Dinh
Journal:  J Bacteriol       Date:  2008-02-29       Impact factor: 3.490

3.  Depletion of antibiotic targets has widely varying effects on growth.

Authors:  Jun-Rong Wei; Vidhya Krishnamoorthy; Kenan Murphy; Jee-Hyun Kim; Dirk Schnappinger; Tom Alber; Christopher M Sassetti; Kyu Y Rhee; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

4.  Square-wave adsorptive anodic stripping voltammetric determination of norfloxacin using a glassy carbon electrode modified with carbon black and CdTe quantum dots in a chitosan film.

Authors:  Anderson Martin Santos; Ademar Wong; Fernando Henrique Cincotto; Fernando Cruz Moraes; Orlando Fatibello-Filho
Journal:  Mikrochim Acta       Date:  2019-02-02       Impact factor: 5.833

5.  Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.

Authors:  Wei-Lun Huang; Ting-Lin Chi; Mei-Hua Wu; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

6.  Gamblers: An Antibiotic-Induced Evolvable Cell Subpopulation Differentiated by Reactive-Oxygen-Induced General Stress Response.

Authors:  John P Pribis; Libertad García-Villada; Yin Zhai; Ohad Lewin-Epstein; Anthony Z Wang; Jingjing Liu; Jun Xia; Qian Mei; Devon M Fitzgerald; Julia Bos; Robert H Austin; Christophe Herman; David Bates; Lilach Hadany; P J Hastings; Susan M Rosenberg
Journal:  Mol Cell       Date:  2019-04-01       Impact factor: 17.970

7.  Long depletion time of enrofloxacin in rainbow trout (Oncorhynchus mykiss).

Authors:  Dario Lucchetti; Laura Fabrizi; Emilio Guandalini; Elisabetta Podestà; Luigi Marvasi; Anna Zaghini; Ettore Coni
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Incidence of antibiotic resistance in Campylobacter jejuni isolated in Alberta, Canada, from 1999 to 2002, with special reference to tet(O)-mediated tetracycline resistance.

Authors:  Amera Gibreel; Dobryan M Tracz; Lisa Nonaka; Trinh M Ngo; Sean R Connell; Diane E Taylor
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.

Authors:  Rudolph S Wagner; David B Granet; Steven J Lichtenstein; Tiffany Jamison; Joseph J Dajcs; Robert D Gross; Paul Cockrum
Journal:  Clin Ophthalmol       Date:  2010-02-02

10.  Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol.

Authors:  Thirunavukkarasu Annamalai; Neil Dani; Bokun Cheng; Yuk-Ching Tse-Dinh
Journal:  BMC Biochem       Date:  2009-06-11       Impact factor: 4.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.